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Background:  Long-term  outcome  and  safety  concerns  regarding  drug-eluting  stents  (DES)  for  acute
myocardial  infarction  (AMI)  treatment  is  still  debated.
Methods  and  results:  We  analyzed  data  from  1937  patients  with  complete  5-year  follow-up  (94.5%)  from
a  multicenter  registry  of sirolimus-eluting  stents  (J-PMS).  The  patients  were  divided  into  2  groups:  AMI
(n =  133)  and  non-AMI  (n =  1804)  by  clinical  presentation  of  index  procedure,  and  compared  the  outcomes.
At  5-year  follow-up,  there  were  no  signiﬁcant  differences  in major  adverse  cardiac  events  (MACE),  death,
MI,  or  stent  thrombosis  between  the  groups.  However,  target  vessel  related  events  (TVF;  revasculariza-
tion,  cardiac  death,  MI, thrombosis)  were  higher  in the  non-AMI  group  (p = 0.03).  In the  early  phase  (0–6
months),  MACE  and  death/MI  were  higher  in the  AMI  group  (6.0%  vs. 3.0%;  p  = 0.02 and  6.8%  vs.  2.1%;
p  <  0.001).  However,  in  the  late phase  (6–60  months),  there  was  a difference  in TVF  between  the  2  groups,
with  a steady  increase  in  the  non-AMI  group  (p = 0.03).  Over  60%  of patients  with  AMIs  were  started
on  dual  antiplatelet  therapy  after  stent  implantation  or on the  same  day.  However,  dual  anti-platelet
therapy  duration  was similar  (867  ±  18 days  in  the  AMI  and  727  ± 57  days  in  the  non-AMI  group,  p =  0.5).
Frequency  of  bleeding  was similar.
Conclusion:  Five-year  observation  of AMI  treatment  using  drug-eluting  stent  compared  with  non-AMI
has  no  clinical  disadvantage.
3  Jap© 201
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Although most worldwide registry and meta-analysis data sup-
ort the effectiveness of drug-eluting stent (DES) implantation for
he treatment of acute myocardial infarction (AMI) [1–3], some
onﬂicting results have been reported [4]. Pathological inves-
igations claim that there are risks with DES for AMI  during
ercutaneous coronary intervention (PCI) [5–7], but do not address
he long-term safety of DES. In addition, the Japanese experience
ith AMI  treatment using DES has not been well assessed [8]. Given
his context, we investigated whether DES implantation for AMI
hould be discriminated from routine PCI using DES from 5 years of
xperience.
DOI of commentary article: http://dx.doi.org/10.1016/j.jjcc.2013.02.016.
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Methods
Patient selection
The CypherTM Stent Japan Post-Marketing Surveillance Registry
(J-PMS) is a post-marketing surveillance program mandated by
the Japanese government as one of the conditions for regulatory
approval. The study outline has been previously described [9,10].
Brieﬂy, 2050 consecutive patients who  underwent sirolimus-
eluting stent (SES) implantation between September 2004 and
September 2005 at 50 institutions representative of the clinical
environment across Japan were enrolled. The indications for SES
implantation were left to the discretion of each participating car-
diologist. In this study, we  analyzed 1937 patients with complete
5-year follow-up data (94.5% of the cohort). The patients analyzed
were divided into 2 groups according to AMI  status based on the
clinical presentation during the index procedure. The AMI  group
(n = 133) included patients who received emergent acute infarct
angioplasty (n = 84, 63.2%). The non-AMI group (n = 1804) included
vier Ltd. All rights reserved.
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Table 1
Patient characteristics.
AMI
(n = 133)
Non-AMI
(n = 1804)
P-Value
Mean age, years 66.9 ± 11.7 (133) 67.2 ± 9.7 (1804) 0.86
Age  ≥ 75 years 40 (30.1) 431 (23.9) 0.12
Male sex 106 (79.7) 1358 (75.3) 0.30
LVEF < 30% 9 (8.1) 52 (3.4) 0.02
BMI, kg/m2 24.2 ± 3.8 (132) 24.0 ± 3.2 (1799) 0.97
Previous MI  25 (18.8) 720 (39.9) <0.001
Previous PCI 28 (21.1) 1065 (59.0) <0.001
Previous CABG 1 (0.8) 158 (8.8) <0.001
Diabetes 47 (35.3) 795 (44.1) 0.06
Insulin treated diabetes 9 (6.8) 189 (10.5) 0.23
Dialysis 3 (2.3) 97 (5.4) 0.15
Hypertension 82 (61.7) 1273 (70.6) 0.04
Dyslipidemia 61 (45.9) 1043 (57.8) 0.01
Peripheral vascular disease 6 (4.5) 119 (6.6) 0.46
Cerebrovascular disease 10 (7.5) 138 (7.6) 0.95
Family history of CAD 12 (9.0) 119 (6.6) 0.28
Current smoker 49 (36.8) 316 (17.5) <0.001
Multi-vessel disease 68 (51.1) 729 (40.4) 0.02
AMI, acute myocardial infarction; LVEF, left ventricular ejection fraction; BMI,
body mass index; MI,  myocardial infarction; PCI, percutaneous coronary interven-
tion; CABG, coronary artery bypass graft; CAD, coronary artery disease. Values are
means ± SD (n) or n (%).
Table 2
Lesion characteristics.
AMI  (n = 133) Non-AMI (n = 1804) P-Value
Number of lesions 147 2168
Target vessel 0.41
RCA  40 (27.2) 666 (30.7) 0.41
LAD  73 (49.7) 943 (43.5) 0.15
LCX  27 (18.4) 476 (22.0) 0.35
LMT  7 (4.8) 83 (3.8) 0.51
ACC/AHA type B2/C 123 (86.6) 1743 (80.6) 0.08
De  novo 144 (98.0) 1681 (77.5) <0.001
In-stent restenosis 2 (1.4) 340 (15.7) <0.001
Concentric 66 (46.8) 959 (45.5) 0.80
Mod./sev. calciﬁcation 21 (14.3) 375 (17.3) 0.43
Bifurcation 57 (38.8) 715 (33.0) 0.15
Ostial location 22 (15.0) 377 (17.4) 0.50
Total occlusion 47 (32.0) 207 (9.5) <0.001
QCA  data
Lesion length, mm 17.4 ± 10.4 17.4 ± 10.2 0.85
Ref.  diameter, mm 2.53 ± 0.58 2.57 ± 0.60 0.94
MLD
Pre,  mm 0.49 ± 0.49 0.77 ± 0.48 <0.001
Post, mm 2.29 ± 0.68 2.25 ± 0.66 0.42
%  DS
Pre, % 80.7 ± 18.3 70.6 ± 16.6 <0.001
Post, % 19.2 ± 13.2 19.0 ± 13.8 0.86
Procedural data
Direct stenting 37 (25.2) 472 (21.8) 0.35
Rotablator usage 0 (0.0) 91 (4.2) 0.004
IVUS usage 107 (72.8) 1582 (73.0) 0.96
Maximum pressure, atm 16.0 ± 4.0 (197) 16.0 ± 3.5 (2899) 0.67
Stent diameter, mm 3.05 ± 0.36 (197) 2.99 ± 0.36 (2900) 0.03
Total stent length, mm 29.5 ± 14.1 (147) 28.7 ± 14.9 (2168) 0.25
Number of stents per patient 1.48 ± 0.74 (133) 1.60 ± 0.82 (1804) 0.10
Number of stents per lesion 1.34 ± 0.59 (147) 1.34 ± 0.60 (2168) 0.97
Post-dilatation 75 (51.0) 1002 (46.2) 0.27
AMI, acute myocardial infarction; RCA, right coronary artery; LAD, left anterior
descending; LCX, left circumﬂex; LMT, left main trunk; ACC/AHA, American Col-
lege of Cardiology/American Heart Association; Mod./Sev., moderate or severe; QCA,22 T. Adachi et al. / Journal of
72 (15.1%) patients with on-label lesions. AMI  was deﬁned accord-
ng to the criteria of each participating institution. The method used
o measure the left ventricle ejection fraction (LVEF) depended on
ach institution. Any method of the following was  available for
ecords: echocardiography, left ventriculography, and radioisotope
maging.
In this study, we clariﬁed the long-term clinical outcomes,
ncluding dual anti-platelet therapy (DAPT) duration after SES
mplantation, in the AMI  and non-AMI groups. In addition, we
ncluded a speciﬁc analysis of long-term events associated with
he infarct-related artery (IRA).
ata collection and outcomes
The post-marketing surveillance databases were developed by
he Japanese branch of Johnson & Johnson (Warren, NJ, USA).
ollow-up data were collected at 3, 8, and 12 months, and annually
hereafter up to 5 years. An independent safety and efﬁcacy evalua-
ion committee adjudicated all reported and suspected events. The
tudy was designed to focus on IRA failure, which corresponds to
arget vessel failure (TVF) in the non-AMI group. TVF was deﬁned as
ardiac death, recurrent MI,  target vessel revascularization (TVR),
nd thrombosis associated with the IRA. Death was classiﬁed as all-
ause or non-cardiac death. TVR was deﬁned as a combination of
arget lesion revascularization (TLR) and revascularization remote
rom target lesion in the IRA territory (non-TL TVR). A major adverse
ardiac event (MACE) was deﬁned as a composite of all-cause death,
I,  any TLR, and thrombosis. In this study, lesions meeting the
cademic Research Consortium criteria for deﬁnite and probable
tent thrombosis were considered stent thrombosis [11]. Bleed-
ng deﬁnition was according to BARC (Bleeding Academic Research
onsortium) deﬁnition: Type 2, 3, and 5 were included for this study
12].
tatistical analysis
Continuous variables are expressed as means ± standard devi-
tion (SD) and categorical data are presented as frequencies. For
omparisons between groups, the chi-square test, Fisher’s exact
est, or the Wilcoxon rank-sum test was used as appropriate.
ime-to-event data are presented as Kaplan–Meier estimates, and
alues are expressed as means ± standard error of the mean (SEM).
urvival analysis was performed using a log-rank test or Cox pro-
ortional hazards regression modeling with a step-wise selection
rocess. Landmark analysis was performed to assess events occur-
ing in different time periods. The landmark point was set at 6
onths from the index procedure to avoid life-threatening con-
itions inherent to AMI. A p-value less than 0.05 was  considered
tatistically signiﬁcant. Statistical analyses were performed with
AS software, version 9.1.3 (SAS Institute, Cary, NC, USA).
esults
atient and lesion characteristics
Patient characteristics of the 2 groups are shown in Table 1.
 higher proportion of patients in the AMI  group had LVEF < 30%
p = 0.019) and multi-vessel disease (p = 0.02), but there was a
igher proportion of patients with a history of MI or previous
evascularization in the non-AMI group (p < 0.001). Hypertension
p = 0.04) and dyslipidemia (p = 0.008) were more frequently seen
n the non-AMI group, but there was a higher percentage of current
mokers in the AMI  group (p < 0.001).
Lesion characteristics are presented in Table 2.The number of
e novo lesions and occluded vessels was higher in the AMI  group
p < 0.001), but there were no signiﬁcant differences in parameters
quantitative coronary angiography; MLD, minimal luminal diameter; % DS, percent
diameter stenosis; IVUS, intravascular ultrasound. Values are means ± SD n (%).
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elated to target vessel distribution, lesion complexity, frequency
f type B2/C lesions, calciﬁcation, bifurcation, and ostial loca-
ion between the 2 groups. Pre-procedural quantitative coronary
ngiography parameters of the AMI  group revealed a smaller mini-
al  lumen diameter and more severe stenosis (p < 0.001), but refer-
nce vessel diameter and lesion length were similar in the 2 groups.
ive-year clinical outcomes
Clinical outcomes at 5 years are listed in Table 3. At the 5-
ear follow-up, there were no statistically signiﬁcant differences
n MACE, death, MI,  and frequency of stent thrombosis between
he AMI  and non-AMI groups. Only one patient in the AMI  group
resented with a very late stent thrombosis (0.8%). The accumu-
ated number of TVF was signiﬁcantly higher in the non-AMI group
p = 0.032). To assess the impact of DES on local conditions, i.e. vul-
erable plaque, necrotic core, and thrombus, we compared patients
ho received emergent intervention for AMI  to patients with on-
abel lesions in the non-AMI group as a sub-analysis. However,
here were no remarkable differences in the 5-year clinical results
etween these lesion subsets (Fig. 1).vent accumulation and landmark analysis at 6 months
Event frequency curves for MACE, death/MI, TLR, and TVF are
hown in Fig. 2. In the early phase (0–6 months), the frequency of
able 3
linical outcomes at 5 years.
AMI
(n = 133)
Non-AMI
(n = 1804)
P-Value
MACE 32 (24.1) 417 (23.1) 0.83
Death 21 (15.8) 238 (13.2) 0.43
Cardiac death 5 (3.8) 89 (4.9) 0.68
Non-cardiac death 16 (12.0) 149 (8.3) 0.15
MI  5 (3.8) 60 (3.3) 0.80
Q-wave MI  2 (1.5) 24 (1.3) 0.70
Emergency CABG 1 (0.8) 2 (0.1) 0.19
TLR  7 (5.3) 178 (9.9) 0.09
TVR  15 (11.3) 291 (16.1) 0.17
Non-target lesion TVR 10 (7.5) 171 (9.5) 0.54
TVF  17 (12.8) 371 (20.6) 0.03
Deﬁnite/probable stent thrombosis 1 (0.8) 24 (1.3) 0.54
MI, acute myocardial infarction; MACE, major adverse cardiac event; MI,
yocardial infarction; CABG, coronary artery bypass graft; TLR, target lesion revas-
ularization; TVR, target vessel revascularization; TVF, target vessel failure. Values
re  n (%).
ig. 1. Relationship between clinical outcome and target lesion condition after drug-elu
ardiac  event; MI,  myocardial infarction; TLR, target lesion revascularization; TVR, targ
nterval.ology 61 (2013) 321–325 323
MACE and all-cause death/MI was  higher in the AMI  group (6.0%
vs. 3.0%; p = 0.02 and 6.8% vs. 2.1%; p < 0.001). However, in the late
phase (6–60 months) difference was observed only in the TVF event
rate between the 2 groups; the number of events associated with
the target vessel in the non-AMI group steadily increased as com-
pared to the IRA of AMI  group (p = 0.03). There was no difference
in the frequency of angiography during the late phase between
the two groups (83.4% [111/133] in AMI  and 87.2% [1573/1804]
in non-AMI, p = 0.229).
DAPT and bleeding
Details on the introduction and continuation of DAPT during the
5 years of the study are shown in Fig. 3. In this study, over 60% of
patients with AMIs were started on DAPT after stent implantation
or on the same day. Conversely, over 60% of the non-AMI group
started DAPT at least 3 days before DES implantation (p < 0.001).
However, there were no differences in rates of DAPT continuation,
based on the frequency of drop-out ratio, throughout the 5-year
period. Mean DAPT duration between the 2 groups was similar
(867 ± 18 days in the AMI  group and 727 ± 57 days in the non-AMI
group, p = 0.5). Bleeding was  observed in 59 of 1937 patients (3.0%)
at 5 years. Of these, 5 patients were in the AMI  group (8.5%, p = 0.6).
Discussion
Safety issues regarding DES use during acute infarct angioplasty
involved concerns over stenting ruptured or thrombotic segments
of vulnerable vessels and the uncertain risk of future bleeding and
tolerance of DAPT. The current study does not show a marked
increase in worse outcomes in AMI  patients who  received DES com-
pared to non-AMI controls over a 5-year observation period. Both
DAPT continuation duration and frequency of bleeding were similar
in the 2 groups. Several meta-analyses and randomized trials with
head-to-head comparisons between DES and bare-metal stents
(BMSs) for AMI  have already been reported in the early DES era
[1–3,13]. These reports similarly showed no signiﬁcant differences
in hard endpoints such as death, recurrent MI, or stent thrombosis,
but the rate of repeat revascularization, re-stenosis, or re-occlusion
have been signiﬁcantly lower in patients receiving DES. These stud-
ies have clariﬁed device-speciﬁc differences in the treatment of
AMI. However, AMI  treatment using BMS  also carries the potential
of event occurrence. Conversely, comparison of the clinical pre-
sentation (i.e. stable angina, AMI) among all patients treated by
DES can better predict disease- or lesion-speciﬁc outcomes. In the
ting stent implantation. emAMI, acute infarct angioplasty; MACE, major adverse
et vessel revascularization; TVF, target vessel failure. CI indicates conﬁdence of
324 T. Adachi et al. / Journal of Cardiology 61 (2013) 321–325
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dig. 2. Cumulative incidence of the events in the AMI  and non-AMI groups during
ACE,  major adverse cardiac event; all cause death/MI, composite of all cause death
urrent registry, we eliminated early events attributable to AMI
tself through landmark analysis, and clariﬁed the differences
n long-term outcomes among patients with DES implantation
ccording to AMI status. Similar approaches have been used in
revious large-scale DES registries [14,15]. Based on another large-
cale Japanese registry, the J-Cypher study presented a similar
ncidence of death and MI  between patients with and without acute
oronary syndrome after 2 years of follow-up [14]. The e-Cypher
ig. 3. Use of dual anti-platelet therapy (DAPT) in the AMI  and non-AMI groups
uring 5 years of observation. AMI, acute myocardial infarction.ars of observation: 6-month landmark analysis. AMI, acute myocardial infarction;
yocardial infarction; TLR, target lesion revascularization; TVF, target vessel failure.
registry included 1883 patients with MI,  but DES  has not been
shown as a predictor of both MACE and stent thrombosis [15].
Pathologically and clinically based lesion-speciﬁc studies of the
relationship between pre-stenting lesion conditions and the type
of device used are more likely to warn against DES implantation
in the IRA or culprit lesion. Such studies have focused on the heal-
ing process and neoatherosclerosis after DES vs. BMS  implantation
and the occurrence rates of thrombotic events [4,6,16]. Nakazawa
et al. compared cases of DES implanted within 30 days of AMI  with
stable angina on pathological parameters, and found that vessel
healing after DES implantation for AMI  was  substantially delayed
when compared with stable angina, emphasizing the importance of
underlying plaque morphology in the arterial response to DES [5,7].
Kang and colleagues reported that the number of neoatheroscle-
rotic optical coherence tomography ﬁndings was  greater in patients
with an unstable clinical presentation during the index procedure
[16]. An angiography-oriented clinical study showed a correlation
between angiographic lesion features and the late clinical events
in patients with DES implantation to treat ST-segment elevation
MI  [17]. The study reported that large thrombus burden was an
independent predictor of mortality and MACE, and large throm-
bus at presentation was  also an independent predictor of stent
thrombosis. These interesting insights were enough to send a cau-
tionary message to clinicians. However, the long-term outcomes
of DES implantation in the IRA remain unclear, because the obser-
vation period of available studies was  not long enough to assess
safety concerns. In the current study, although a higher frequency
of death/MI within 6 months was seen in the AMI  vs. the non-AMI
group, a difference throughout the 5-year observation period was
not observed. Instead, after the 6-month landmark point, all events
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ssociated with the IRA, i.e. TVFs, were signiﬁcantly increased in the
on-AMI group, in contrast to previous knowledge and hypotheses
18,19]. There are several speculations. First, no further inten-
ive care would be performed on the IRA. Only vessels supplying
iable muscle received detailed follow-up and/or treatment. Sec-
nd, AMI patients might have received more secondary preventive
are than patients with chronic ischemic heart disease. Reports
n statin therapy for IRA (i.e. target vessel of AMI) have shown
ramatic plaque regression compared to chronic coronary artery
isease [20,21]. Third, it might be due merely to the difference in
he backgrounds, such as frequency of in-stent restenosis and stent
iameter.
There were several limitations in this study. There were rel-
tively small numbers of patients in the AMI group. Details on
he admission status, such as the presence of shock and infarct
ize, were not available. However, the main purpose of this study
as to investigate long-term outcomes and the investigation was
ocused on safety concerns of patients with AMI  when compared to
on-AMI patients who do not have a life-threatening presentation.
oreover, we  employed landmark analysis to avoid issues related
o the clinical condition at admission. The study was  designed
ith consecutive patient enrollment, but the registered population
ncluded only patients who received at least one DES. Therefore,
he enrolled AMI  population might be affected by selection bias.
ecause long-term medication data other than DAPT had been con-
idered to be unimportant for post-marketing study of DES, these
ata lacked. The current study only investigated ﬁrst-generation
tents, but this SES has already been replaced by subsequent gen-
rations, on which there is little long-term safety data. In contrast,
he high long-term follow-up rate in this study provides valuable
nformation, especially for current clinical practice in Japan.
onclusion
Five-year observation of AMI  treatment using DES compared
ith non-AMI has no clinical disadvantage, i.e. increase in death/MI,
leeding, revascularization, or discontinuation of DAPT.
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